THE ROLE OF STEROID ER, AR RECEPTORS, BRN-3Α AND TRIM16 NUCLEAR TRANSCRIPTION FACTORS IN THE DEVELOPMENT OF KIDNEY CANCER

DOI: https://doi.org/10.29296/24999490-2018-05-10

1-Cancer Research Institute of the Tomsk National Research Medical Center, Kooperatyvny by-street, 5, Tomsk, 634050, Russian Federation; 2-Siberian State Medical University, Moskovsky trakt, 2, Tomsk, 634050, Russian Federation Е-mail: [email protected]

Introduction. The study of molecular mechanisms of the development of kidney cancer is one of the actual problems in oncology. There is conflicting information about the importance of steroid hormone receptors in the kidney cancer. The aim of the study was to investigate the expression of ERα, ERβ, AR in the clear cell cancers of the kidney in dependence on the tumorigenesis in association with the mRNA level and the content of the nuclear transcription Brn-3α and TRIM16 factors. Methods. The study included 40 patients with renal cell carcinoma. T2N0M0, the stage of the disease was fixed in 25 people, and 15 had disseminated disease at the stage T2-3N0M1. The expression of ERα, ERβ, Brn-3α, and TRIM16 was determined by real-time PCR. The content of Brn-3α, TRIM16 factors was evaluated by Western Blotting. Results. The observed changes in AR, ERα, ERβ expression didn’t dependent on the tumor size. They were associated with the development of metastases. In metastatic cancers was revealed 1,79; 3,96 and a 10,6-fold increase of these indices in comparison with to non-metastatic ones. In patients, at T3-4T0M0 stage the Brn-3α expression was 1,9 times higher than in cases at the stage T1-2N0M. There was noted an enhancement of Brn-3α content by 5,7 times was associated with the elevated content and expression of TRIM16. Conclusion. The ER, AR overexpression in the primary tumor tissue was revealed in the development of metastases, probably, due to the influence of the Brn-3α nuclear transcription factor on their transcriptional activity. Change in TRIM16 expression and protein content was also associated with tumor spreading, which however requires further study.
Keywords: 
kidney cancer, estrogen receptors, androgen receptors, nuclear factor Brn-3α, TRIM16 transcription factor
Список литературы: 
  1. Joosten S.C., Hamming L., Soetekouw P.M., Aarts M.J., Veeck J., van Engeland M., Tjan-Heijnen V.C. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015; 855: 1–16.
  2. Spirina L.V., Usynin E.A., Kondakova I.V., Yurmazov Z.A., Slonimskaya E.M. Vliyanie targetnoy terapii na soderzhanie transkripcionnyh, rostovyh faktorov, proteinkinazy TOR i aktivnosti vnutrikletochnyh proteinaz u bol`nyh disseminirovannym rakom pochki. Byulleten` e`ksperimental`noy biologii i mediciny. 2015; 60 (6): 768–72. [Spirina L.V., Usynin E.A., Kondakova I.V., Yurmazov Z.A., Slonimskaya E.M. Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma. Bull Exp. Biol. Med. 2016; 60 (6): 798–801 (in Russian)]
  3. Spirina L.V., Gorbunov A.K., Chigevskaya S.Y., Kondakova I.V., Slonimskaya E.M., Usynin E.A., Choinzonov E.L., Zaitseva O.S. Transcription factor Brn-3a mRNA in cancers, relationship with AR, ER receptors and AKT/m-TOR pathway components. AIP Conference Proceedings. 1882, 020071 (2017). https://doi.org/10.1063/1.5001650.
  4. Langner C., Ratschek M., Rehak P., Schips L., Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J. Urol. 2004; 171 (2 Pt 1): 611–4.
  5. Bennett N.C., Rajandram R., Ng K.L., Gobe G.C. Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma. J. of Kidney Cancer and VHL. 2014; 1 (2): 17–25.
  6. Chen K.C., Lin C.M., Huang C.J., Hen S.K., Wu S.T., Chiang H.S., Ku W.C. Dual roles of 17-β estradiol in estrogen receptor-dependent growth inhibition in renal cell carcinoma. Cancer genomics and proteomics. 2016; 13 (3): 219–30.
  7. Yu C.P., Ho J.Y., Huang Y.T., Cha T.L., Sun G.H., Yu D.S., Chang F.W., Chen S.P., Hsu R.J. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation. PLoS One. 2013; 8 (2): e56667. https://doi.org/10.1371/journal.pone.0056667. Epub 2013 Feb 27.
  8. Huang Q., Sun Y., Ma X., Gao Y., Li X., Niu Y., Zhang X., Chang C. Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma. Nat Commun. 2017; 8 (1): 918. https://doi.org/10.1038/s41467-017-00701-6.
  9. He D., Li L., Zhu G., Liang L., Guan Z., Chen S., Yeh S., Chang C. New therapy via targeting androgen receptor→HIF-2α→VEGF signals with ASC-J9® to suppress renal cell carcinoma progression. Cancer Research. 2014. https://doi.org/10.1158/0008-5472.CAN-13-2681.
  10. Guan Z., Li C., Fan J., He D., Li L. Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling. Sci Rep. 2016; 6: 37085. https://doi.org/10.1038/srep37085.
  11. Zhai W., Sun Y., Jiang M., Wang M., Gasiewicz T.A., Zheng J., Chang C. Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia. Oncogene. 2016; 35 (37): 4866–80. https://doi.org/10.1038/onc.2016.19. Epub 2016 Mar 14.
  12. Berwick D.C., Diss J.K., Budhram-Mahadeo V.S., Latchman D.S. A simple technique for the prediction of interacting proteins reveals a direct Brn-3a-androgen receptor interaction. J. Biol. Chem. 2010; 285 (20): 15286–95. https://doi.org/10.1074/jbc.M109.071456. Epub 2010 Mar 12.
  13. Budhram-Mahadeo V., Fujita1 R., Bitsi S., Sicard P., Heads R. Co-expression of POU4F2/Brn-3b with p53 may be important for controlling expression of pro-apoptotic genes in cardiomyocytes following ischaemic/hypoxic insults. Cell Death and Disease. 2014; 5: 1503. https://doi.org/10.1038/cddis.2014.452.
  14. Tan C., Takayama T., Takaoka N., Fujita H., Miyazaki M., Sugiyama T., Ozono S. Impact of gender in renal cell carcinoma: the relationship of FABP7 and BRN2 expression with overall survival. Clinical Medicine Insights Oncology. 2014; 8: 21–7. https://doi.org/10.4137/CMO.S13684.
  15. Ozato K., Shin D.M., Chang T.H., Morse H.C. 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008; 8 (11): 849–60.
  16. Kim P.Y., Rahmanto A.S., Tan O., Norris M.D., Haber M., Marshall G.M., Cheung B.B. TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells. Apoptosis. 2013; 18 (5): 639–51.
  17. Tan H., Liu Z., Qi J., Chu G. Tripartite motif 16 inhibits the migration and invasion in ovarian cancer cells. Oncol Res. 2017; 25 (4): 551–8.